Aprotinin is a medicine that helps stop blood from leaking out of blood vessels. It's used in certain surgeries, like heart surgery, to reduce bleeding and the need for blood transfusions. It's made from a type of protein found in cows.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Aprotinin is a medicine that reduces bleeding during heart surgery. Given into a vein under the brand name Trasylol, it was approved in the US to cut blood loss and the need for blood transfusions in people at higher risk of heavy bleeding during coronary artery bypass graft (CABG) surgery, the operation that reroutes blood around blocked heart arteries using a heart-lung machine. Intravenous aprotinin is no longer sold in the United States. Its maker suspended sales in 2007 and removed remaining supplies in 2008, after a large trial found more deaths with aprotinin than with two other bleeding-control medicines. In Europe, regulators reviewed the evidence again and allowed it back in 2012, but only for adults at high risk of major blood loss having bypass surgery alone, not combined with other heart operations. In US hospitals, tranexamic acid and aminocaproic acid fill this role. Aprotinin also appears in a different form: a synthetic version is one ingredient in some fibrin sealants, surgical "tissue glues" such as TISSEEL, which surgeons apply directly to tissue to help control bleeding. That is the form people in the US are now most likely to encounter.
When the body forms a blood clot, it also starts enzymes that later break the clot down. Plasmin is the main clot-dissolving enzyme, and kallikrein helps drive inflammation and clotting activity. Heart-lung bypass strongly activates both systems, which can lead to oozing and extra blood loss. Aprotinin is a small protein, originally obtained from cow lung tissue, that blocks these enzymes. By slowing the breakdown of fresh clots and damping the inflammatory response to bypass, it helps clots hold, so less blood is lost. In a fibrin sealant, the synthetic aprotinin does the same job locally, keeping the sealant's clot from dissolving too quickly.
Intravenous aprotinin is only given by the anesthesia team in the operating room, through a central line (a catheter in a large vein). Because allergic reactions are its main danger, a small test dose is given first, at least 10 minutes before the full dose, while the patient is under anesthesia and the team is ready to start the heart-lung machine immediately. A tolerated test dose does not guarantee the full dose will be tolerated. The full dose is a slow loading dose, a dose added to the heart-lung machine's fluid, and a continuous drip for the rest of the operation. There is nothing for the patient to take or manage at home. Fibrin sealants containing aprotinin are applied by the surgeon during the operation.
Because aprotinin is given during surgery under anesthesia, a patient does not usually notice its effects directly. The care team watches for them. The most serious risk is a severe allergic reaction (anaphylaxis), which can appear as a sudden drop in blood pressure, wheezing or a rash, and can be fatal. These reactions are rare in people who have never had aprotinin before and become more likely with repeat exposure. If one occurs, the team stops the drug and treats it on the spot. Aprotinin can also strain the kidneys. In studies, rises in creatinine (a blood test of kidney function) were somewhat more common with aprotinin than with placebo. Most were mild and settled, but some people developed kidney failure, so kidney blood tests are checked after surgery. Giving the loading dose too quickly can briefly lower blood pressure. Blood clots, including heart attack and blockage of a new bypass graft, are listed among its serious reactions.
The key warning is about previous exposure. Anyone who has received aprotinin within the past 12 months should not receive it again, because the risk of a life-threatening allergic reaction is highest then, and reactions have occurred even after longer gaps. Earlier exposure can be hard to remember because it often happened during a past operation, including through a fibrin sealant such as TISSEEL. People who have had heart surgery or another operation in the past year, or a known reaction to aprotinin or a surgical sealant, should make sure the surgical team knows. The same allergy concern applies to fibrin sealants that contain aprotinin. The drug's safety record is disputed. The 2008 BART trial (Blood Conservation Using Antifibrinolytics in a Randomized Trial), in about 2,300 high-risk heart surgery patients, found that aprotinin slightly reduced massive bleeding but was linked to more deaths within 30 days than tranexamic acid or aminocaproic acid, which led to its US withdrawal. European regulators later judged that trial flawed and concluded that a higher death risk could be neither confirmed nor ruled out, which is why European use is limited to a narrow group of patients. The kidney risk is higher in people who already have reduced kidney function or who receive aminoglycosides, a group of strong antibiotics that can also affect the kidneys. Aprotinin also changes the results of some clotting tests, so the team adjusts how it monitors heparin, the blood thinner used during bypass.
If aprotinin is part of your surgery, its effects happen while you are asleep and the anesthesia team manages them. Afterward, the main things to expect are routine checks of bleeding, blood counts and kidney function in the days following the operation. The lasting practical point is your medical record. Because a second exposure carries more allergy risk than the first, it helps to know whether aprotinin or an aprotinin-containing sealant was used in an operation, and to mention it before any future surgery. The surgical report or the hospital can confirm this if you are unsure.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Aprotinin, what you've noticed, or ask the community a question.